NRIX stock forecast, quote, news & analysis
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases... Show more
Nurix Therapeutics (NRIX) Stock Analysis: Pipeline Momentum Meets Earnings Hurdles
Key Takeaways
- Nurix Therapeutics reported Q1 2026 net loss of $87.2 million with revenue of $6.3 million, missing estimates, yet ended with $540.7 million in cash.
- Stock trades around $15.60 amid 52-week range of $8.18-$22.50, down recently but up 68% over past year.
- Analysts maintain Strong Buy consensus with average price target of $30, signaling potential upside.
- Key pipeline advances include multiple AACR 2026 presentations and investor conference participation.
- Targeted protein degradation platform progresses with bexobrutideg (NX-5948) in Phase 2 trials for B-cell malignancies.
Current Market Snapshot
In recent trading sessions, Nurix Therapeutics (NRIX) stock has navigated volatility within its broader uptrend, reflecting investor focus on clinical-stage biopharma dynamics. The shares have pulled back from yearly highs amid sector pressures but maintain support above key lows, buoyed by pipeline optimism. Trading volume has spiked around earnings and conference announcements, underscoring sentiment tied to development milestones rather than immediate profitability. Broader biotech trends, including interest in targeted protein degradation (a technology that eliminates disease-causing proteins), continue to influence NRIX's position in the latest market cycle.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the platform's top-performing AI trading bots, curated from hundreds available that analyze and trade thousands of tickers across diverse strategies. These bots employ advanced algorithms, including deep learning and price action analysis, to generate signals in varying market conditions—spanning short-term swings, long-only breakouts, and sector-specific plays like biotech or semiconductors. Recent standouts feature 30-day annualized returns up to 171%, with win rates as high as 100% over select periods (25/25 trades) and others at 88% (15/17 trades), alongside profit factors exceeding 4.0 in volatile environments. Each bot differs in timeframe, risk profile, and focus, such as low-drawdown growth sectors or high-momentum industrials posting up to 80% annualized gains. This dynamic selection highlights bots best suited to current volatility. Investors may explore these for data-driven insights into stocks like NRIX.
Recent Developments Driving NRIX Price Action
Nurix Therapeutics, a clinical-stage biopharmaceutical firm pioneering targeted protein degradation therapies for cancer and autoimmune diseases, has seen its stock react to pipeline visibility and financial updates in recent weeks. On April 8, 2026, the company released Q1 2026 results, posting revenue of $6.3 million—well below the $14.25 million consensus—driven by collaboration agreements, alongside research and development (R&D) expenses of $84.1 million, culminating in a net loss of $87.2 million, or $0.79 per share, wider than the expected $0.76 loss. Despite the miss, cash and marketable securities stood at $540.7 million as of February 28, 2026, providing runway for ongoing trials. The earnings shortfall contributed to intraday pressure, with shares dipping amid heightened volume, though after-hours reaction showed modest resilience at +3.55% initially.
The prior day, April 7, Nurix announced participation in an upcoming investor conference, signaling continued engagement with the Street and potential for pipeline spotlights. Earlier, on March 23, the company revealed multiple presentations at the American Association for Cancer Research (AACR) 2026 Annual Meeting, underscoring the depth of its research pipeline—including lead candidate NX-5948 (bexobrutideg), a BTK (Bruton's tyrosine kinase) degrader in Phase 2 for relapsed/refractory B-cell malignancies and autoimmune conditions, alongside NX-2127, NX-1607 (CBL-B inhibitor), and IRAK4 degrader NX-0479/GS-6791 for inflammatory diseases. This news briefly lifted sentiment, aligning with a 6.9% single-session gain noted around late March, as investors weighed scientific leadership against biotech volatility.
Analyst actions reinforced optimism: Needham reiterated Buy with a $26 target on April 8, while H.C. Wainwright held Buy at $32 in March, contributing to a Strong Buy consensus and $30 average target—implying over 90% upside from recent levels. Macro factors, like biotech sector rotation and interest rate sensitivity for cash-rich developers, amplified price swings. Insider selling by Chief Legal Officer Christine Ring (8,148 shares for $124k on April 2) added mild caution, but overall, developments tied price action to progress in degradation tech collaborations with Gilead, Sanofi, and Pfizer, balancing earnings disappointment with trial advancements.
2026 Outlook and Key Factors to Monitor
As Nurix advances through 2026, focus remains on its targeted protein degradation platform, with bexobrutideg (NX-5948) poised for Phase 2 readouts in B-cell malignancies and autoimmune indications, potentially validating oral BTK degradation beyond inhibitors. Earlier goals outlined pivotal trial initiations like DAYBreak for relapsed/refractory CLL (chronic lymphocytic leukemia), alongside expansions for NX-1607 in immuno-oncology and IRAK4 programs with partners. Cash reserves exceeding $540 million support R&D without near-term dilution risks, though burn rates around $84 million quarterly warrant efficiency monitoring.
Industry trends favoring degraders—offering advantages in resistant tumors—present opportunities, tempered by clinical risks like trial enrollment delays or safety signals. Regulatory milestones, such as FDA orphan designations or IND filings, and partnership milestones from Gilead, Sanofi, and Pfizer could drive value. Competitive positioning in oncology and inflammation, macroeconomic biotech funding environment, and macro factors like interest rates impacting valuations are critical. Investors should track AACR data disclosures, conference updates, and Q2 results for pipeline momentum.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
Momentum Indicator for NRIX turns positive, indicating new upward trend
NRIX saw its Momentum Indicator move above the 0 level on March 31, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 84 similar instances where the indicator turned positive. In of the 84 cases, the stock moved higher in the following days. The odds of a move higher are at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for NRIX just turned positive on March 25, 2026. Looking at past instances where NRIX's MACD turned positive, the stock continued to rise in of 40 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where NRIX advanced for three days, in of 246 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 50 cases where NRIX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
NRIX moved below its 50-day moving average on April 08, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NRIX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
NRIX broke above its upper Bollinger Band on April 07, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for NRIX entered a downward trend on April 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.492) is normal, around the industry mean (26.133). P/E Ratio (0.000) is within average values for comparable stocks, (45.240). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.782). Dividend Yield (0.000) settles around the average of (0.034) among similar stocks. P/S Ratio (21.097) is also within normal values, averaging (316.299).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. NRIX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NRIX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a biopharmaceutical company, which focuses on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders
Industry Biotechnology